Lundbeck has come this far with Alzheimer’s vaccine
Lundbeck has seen notable advances for its vaccine candidate against Alzheimer’s, Vaccinil, as of late. For some time the vaccine has been “heading into phase I studies”, but now the company is becoming more specific in regards to the timeframe.
by Benjamin Werner Christensen
For some time, Lundbeck has worked intensely on developing a vaccine against Alzheimer’s disease, giving them a potential new candidate on the highly attractive dementia market, which is currently estimated at around DKK 55 billion (USD 9.84 billion) – a number that is bound to go up in coming years due in part to the demographic development on many of the major markets.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
